Julian Symons
Chief Tech/Sci/R&D Officer en ALIGOS THERAPEUTICS, INC. .
Fortuna: 322 344 $ al 30/04/2024
Perfil
Julian A.
Symons is currently the Chief Scientific Officer & Executive VP at Aligos Therapeutics, Inc. Prior to this, he worked as the Vice President-Disease Area Research & Development at Alios BioPharma, Inc. from 2015 to 2018.
Dr. Symons holds a doctorate degree from York University and an undergraduate degree from the University of Central Lancashire.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 01/03/2024 | 394 064 ( 0.54% ) | 322 344 $ | 30/04/2024 |
Cargos activos de Julian Symons
| Empresas | Cargo | Inicio |
|---|---|---|
| ALIGOS THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/05/2018 |
Antiguos cargos conocidos de Julian Symons.
| Empresas | Cargo | Fin |
|---|---|---|
Alios BioPharma, Inc.
 Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | Corporate Officer/Principal | 01/04/2018 |
Formación de Julian Symons.
| York University | Doctorate Degree |
| University of Central Lancashire | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| ALIGOS THERAPEUTICS, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | Health Technology |
- Bolsa de valores
- Insiders
- Julian Symons
